I83.029 Insurance Policy Changes

ICD-10 I83.029 is officially defined as "Varicose veins of left lower extremity with ulcer of unspecified site." code I83.029 is referenced in 7 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I83.029 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 21, 2026Medium impact
Ultrasound Therapy for Wound Healing (CPB 0746, reviewed 2026-10-16)
Aetna considers ultrasound therapy, including high-frequency ultrasound and non-contact low-frequency ultrasound devices, experimental, investigational, or unproven for wound healing and for reduction of chronic wound pain, because the effectiveness of this approach for these indications has not been established. CPT 97610, low-frequency non-contact non-thermal ultrasound per day, is listed as not covered for the indications in this policy. Examples of ultrasound therapy named in this policy include the FAST procedure, the MIST Therapy System, the Qoustic Wound Therapy System, and the Sonoca 180/185 Wound Care System.
Aetna · Identified Oct 17, 2026Medium impact
Electrical Stimulation for Chronic Ulcers (CPB 0680, reviewed 2026-10-14)
Aetna considers electrical stimulation medically necessary durable medical equipment for arterial ulcers, diabetic ulcers, Stage III or IV pressure ulcers, and venous stasis ulcers when it is used as adjunctive therapy after no measurable signs of healing for at least 30 days of conventional wound treatment. Courses exceeding 1 hour per day are not considered medically necessary, continued stimulation is not medically necessary if measurable healing is not shown within a 4-week treatment period or once the wound bed is 100% epithelialized, and electrical stimulation for chronic ulcers in the home setting is considered not medically appropriate. Aetna considers electrical stimulation experimental, investigational, or unproven for uses including prevention of ulcers and pressure sores, infected wounds, microcurrent as an adjunctive therapy, and the VeinoPlus device for venous ulcers.
Aetna · Identified Aug 18, 2026Medium impact
Ultrasound Therapy for Wound Healing (CPB 0746, reviewed 2025-11-26)
Aetna considers ultrasound therapy for wound healing and for reduction of chronic wound pain experimental, investigational, or unproven, because its effectiveness for these indications has not been established. This includes high-frequency ultrasound and non-contact low-frequency ultrasound devices, such as the MIST Therapy System, the Qoustic Wound Therapy System, and the Sonoca 180/185 Wound Care System. CPT 97610 is listed as not covered for the indications in this policy.
Aetna · Identified Aug 13, 2026Medium impact
Phonophoresis (CPB 0210, reviewed 2026-03-27)
Aetna considers phonophoresis experimental, investigational, or unproven for all indications, including adhesive capsulitis, carpal tunnel syndrome, knee osteoarthritis, low back pain, neck pain, sinusitis, chronic obstructive pulmonary disease, and venous and diabetic ulcers, because its effectiveness has not been established. Controlled clinical trials have failed to demonstrate that phonophoresis increases the rate or extent of absorption of analgesics and anti-inflammatory agents. Bee venom phonophoresis and Contractubex phonophoresis are listed as not covered for the indications in the policy.
Aetna · Identified Aug 13, 2026Medium impact
Pedobarography (CPB 0294, reviewed 2026-04-17)
Aetna considers pedobarography (foot pressure studies) experimental, investigational, or unproven, because the medical literature does not contain reliable evidence that it improves diagnosis and management of foot conditions or health outcomes. CPT 96001, comprehensive computer-based motion analysis with dynamic plantar pressure measurements during walking, is listed as not covered for the indications in this policy. Related CPT codes include motion analysis, surface electromyography and physician interpretation, related HCPCS codes include ankle-foot orthoses and orthopedic shoes, and ICD-10 codes for diabetes with neurological complications, pressure ulcers of the ankle and heel, and osteoarthritis of the ankle and foot are listed as not covered for these indications.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Treatment of Varicose Veins/Venous Insufficiency
Blue Cross Blue Shield Association policy 7.01.124 (BCBSMS policy A.7.01.124) states that treatment of great or small saphenous veins, accessory saphenous veins, varicose tributaries, and perforator veins may be considered medically necessary for symptomatic varicose veins or venous insufficiency when specific criteria are met, and that saphenous vein treatment not meeting those criteria is considered cosmetic and investigational. The policy history shows an update dated 09/22/2026 that changed the policy description, made minor changes to the statements for great or small saphenous veins, accessory saphenous veins, and perforator veins, and re-worded the concurrent treatment statements for accessory saphenous veins and symptomatic varicose tributaries for clarity. Telangiectasia treatment is considered cosmetic and investigational.
Aetna · Identified Sep 29, 2026Low impact
Bio-Surgery: Medicinal Leech Therapy and Medical Maggots (CPB 0556, reviewed 2026-09-01)
Aetna's bio-surgery policy (CPB 0556, reviewed September 1, 2026) sets when medicinal leech therapy and medical maggots (bagged larval therapy) are covered, mainly for specific chronic wounds, flap and replant salvage. It lists many other uses, including knee and thumb osteoarthritis, low back pain and burns, as experimental, and the source gives a review date but no effective date.

Watch I83.029

Get one email when a payer policy names I83.029, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I83.029?

There are 7 tracked policy changes affecting code I83.029, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I83.029?

Payers that have issued tracked updates for code I83.029 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code I83.029 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I83.029. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I83.029?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Ultrasound Therapy for Wound Healing (CPB 0746, reviewed 2026-10-16)

Electrical Stimulation for Chronic Ulcers (CPB 0680, reviewed 2026-10-14)

Ultrasound Therapy for Wound Healing (CPB 0746, reviewed 2025-11-26)

Phonophoresis (CPB 0210, reviewed 2026-03-27)

Pedobarography (CPB 0294, reviewed 2026-04-17)

Treatment of Varicose Veins/Venous Insufficiency

Bio-Surgery: Medicinal Leech Therapy and Medical Maggots (CPB 0556, reviewed 2026-09-01)

What insurance policy changes affect code I83.029?

Which payers have updated policy for code I83.029?

How do I get notified when code I83.029 policy changes?

Why do payers change policies for code I83.029?